Clinical Trial Update: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets [Phase 1]

View source ↗

Summary

Phase 1 study evaluating TQB3720 tablets for metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• TQB3720

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: TERMINATED